Unit Dose Services, LLC
Letter data
- Company
- Unit Dose Services, LLC
- Recipient
- Peter Levasseur | Unit Dose Services, LLC | 20201 Northeast 16th Place | Miami | , | FL | 33179 | United States
- Issue date
- 2022-12-21
- Posted date
- Not available
- FDA office
- Center for Drug Evaluation and Research | CDER
- Subject
- Not available
- Product
- Drugs
- CMS ID
- 636177
- Reference number
- WL 2310
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Unit Dose Services, LLC
MARCS-CMS 636177 —
December 21, 2022
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Reference #:
WL 2310
Product:
Drugs
Recipient:
Recipient Name
Peter Levasseur
Unit Dose Services, LLC
20201 Northeast 16th Place
Miami
,
FL
33179
United States
Issuing Office:
Center for Drug Evaluation and Research | CDER
United States
Dear Mr. Levasseur:
The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter # 2310. Based on our evaluation, it appears that you have addressed the violations contained in this warning letter and corrected the data deficiencies. We have received an updated listing SPL with the correct carton label image for your product and an updated labeler code request SPL with the new contact information. Future FDA regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and to continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Carolyn E. Becker, JD
Director, Office of Unapproved Drugs & Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Content current as of:
12/27/2022
Regulated Product(s)
Drugs